Develops oral treatments for testosterone replacement therapy and neurological disorders.
Jun 2026Revenue $1.57M/yrExpenses $14.1M/yr
No trendCash runway ≈ 2.1 years from Jun 2026
Figures by year
When will Lipocine be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.57M and expenses $14.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.98M | $12.3M | −$10.4M |
| Dec 2024 | $11.2M | $12.4M | −$1.16M |
| Dec 2023 | −$2.85M | $15.1M | −$17.9M |
| Dec 2022 | $500K | $12.6M | −$12.1M |
| Dec 2021 | $16.1M | $13.0M | $3.15M |
| Dec 2020 | $0.00 | $18.0M | −$18.0M |
| Dec 2019 | $165K | $13.1M | −$12.9M |
| Dec 2018 | $428K | $11.8M | −$11.3M |
| Dec 2017 | $0.00 | $21.2M | −$21.2M |
| Dec 2016 | $0.00 | $19.2M | −$19.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.